S-4257-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Jeanne Shaheen (D-NH)
What it does
This bill would raise the annual cap on FDA tobacco product user fees from $712 million to $826.2 million starting in fiscal year 2027, with automatic inflation adjustments in later years. It would extend these user fees to all classes of tobacco products, including e-cigarettes and other "deemed" products that were not previously required to pay fees, and require manufacturers and importers to report sales data to FDA to calculate each company's share.
Who benefits
The FDA's Center for Tobacco Products, which would gain more funding for regulation and enforcement, including public education campaigns on youth e-cigarette use. Public health advocates and communities concerned about youth vaping, since more resources could go toward oversight and enforcement of vaping products. Manufacturers of traditional cigarettes and cigars, who may see their share of the fee burden reduced as e-cigarette and vaping companies begin paying into the same pool.
Who is hurt
E-cigarette and vaping product manufacturers and importers, who would newly owe user fees and face new reporting obligations starting in 2029. Smaller vaping companies with less compliance infrastructure may bear disproportionate administrative burden relative to larger manufacturers. Consumers could see modest price increases if manufacturers pass fee costs through to retail prices.
Supporters argue
Supporters argue that e-cigarette and vaping manufacturers have largely avoided paying their share of FDA regulatory costs even as youth vaping rates have driven a substantial portion of the agency's tobacco oversight workload. They contend that raising and broadening the fee base to include all deemed tobacco products more fairly distributes costs according to market share and gives FDA the resources needed to fund enforcement and youth prevention education, citing years of user fee levels that have not kept pace with inflation or the expanded scope of products FDA regulates.
Opponents argue
Opponents argue that expanding user fees to smaller vaping manufacturers and new product categories could impose disproportionate compliance costs on companies with far less revenue than major cigarette makers, potentially driving smaller or newer market entrants out of business. They contend that reliance on a formula developed later by the Secretary creates uncertainty for industry planning, and that fee increases may ultimately be passed to adult consumers who use vaping products as a smoking-cessation tool rather than solely burdening manufacturers targeting youth.
Constitutional context
Congress's authority to impose these user fees on tobacco manufacturers and importers rests on the Taxing and Spending Clause and Commerce Clause, similar to the funding mechanism upheld in NFIB v. Sebelius (2012) distinguishing permissible taxing/fee authority from compelled commercial activity; here the fees apply only to businesses already engaged in interstate commerce, avoiding the mandate problem at issue in that case.
Checks and balances
Congress sets statutory fee caps and formulas while delegating significant discretion to the FDA Secretary to develop fee-allocation formulas by regulation, with judicial review of those regulations now subject to independent scrutiny post-Loper Bright rather than automatic deference.
Historical precedent
The original tobacco user fee structure was established under the Family Smoking Prevention and Tobacco Control Act of 2009, which this bill amends to expand fee coverage to additional product classes.